 |
 |
 |
 |
|
 |
Myskin™ is a cultured autologous epidermal substitute for the treatment of burns, ulcers and other non-healing wounds. Myskin™ contains living cells expanded from the tissue of individual patients. Each patient treated with Myskin™ receives only their own cells in a viable state designed to initiate wound closure.
Myskin™ comprises a layer of keratinocytes (epidermal cells) on an advanced polymer-like coating which facilitates the transfer of cells into the wound where they can initiate healing. Myskin™ uses a medical grade silicone substrate layer to support cell delivery, wound coverage and allow exudate management.
Myskin™ is produced by CellTran ltd and is available for clinical use by medical professionals. Myskin™ is applied in conjunction with standard dressing regimes and is not limited to a single application, but can be delivered a number of times until wound closure occurs.
Myskin™ was featured on Sky News' medical advances of the year. Click to watch